CRBU Caribou Biosciences Inc.

FDA Catalyst Company
9.95
+0.21  (+2%)
Previous Close 9.74
Open 10.05
52 Week Low 6.41
52 Week High 32.645
Market Cap $604,018,640
Shares 60,705,391
Float 56,748,882
Enterprise Value $218,859,357
Volume 718,094
Av. Daily Volume 688,457
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Citigroup Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/13/2022
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/12/2022
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/10/2022
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/22/2022
RBC Capital Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/18/2022
Brookline Capital Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/14/2022
Oppenheimer Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 12/01/2021
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/30/2021
Citigroup Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/15/2021
Citigroup Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 08/17/2021

Latest News

  1. BERKELEY, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the presentation of studies in primary human T cells highlighting the mechanism underlying the superior specificity of the company's CRISPR hybrid RNA-DNA (chRDNA) guides for genome editing.

    "Our chRDNA guides provide a robust and reproducible approach for maximizing the specificity of CRISPR genome editing, which is key to improving the persistence and potential efficacy of our allogeneic cell therapies," said Steve Kanner, Ph.D., Caribou's chief scientific officer. "Through simple iterative engineering of DNA positions in our chRDNA guides, we optimize the activity…

    View Full Article
  2. -- 100% ORR (5 of 5 patients) and 80% CR (4 of 5 patients) achieved following 1 dose at the
    initial dose level in patients with aggressive r/r B-NHL --

    -- CB-010 is the 1st allogeneic CAR-T cell therapy to achieve 100% ORR (5 of 5 patients) --

    -- Based on promising initial safety profile, ANTLER Phase 1 trial enrolling patients at
    dose level 2 --

    -- CB-010 is the 1st allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-
    editing strategy designed to improve the persistence of antitumor activity --

    -- Caribou webcast conference call planned for today at 10:15 am ET --

    -- Initial data scheduled to be shared at the European Hematology Association (EHA)
    2022 Congress; additional ANTLER data expected by YE 2022

    View Full Article
  3. BERKELEY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of David L. Johnson to its board of directors. Mr. Johnson is a seasoned executive with 30 years of commercial and operational experience in the biopharmaceutical industry.

    "David has an impressive record of successfully building commercial infrastructure and launching new medicines for patients," said Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer. "We are delighted to welcome him to our board of directors and look forward to benefitting from his expertise as we continue to build our company and advance our pipeline of…

    View Full Article
  4. -- Initial ANTLER Phase 1 clinical data scheduled to be shared at the European Hematology Association (EHA) 2022 Hybrid Congress for CB-010, the Company's lead allogeneic cell therapy candidate, in patients with r/r B-NHL --

    -- Submission of IND application planned in H2 2022 for CB-011, Caribou's second allogeneic cell therapy candidate, for evaluation in patients with r/r multiple myeloma --

    -- $390.8 million in cash, cash equivalents, and marketable securities as of March 31, 2022 to advance Caribou's wholly owned pipeline of allogeneic CAR-T and CAR-NK cell therapies --

    BERKELEY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company…

    View Full Article
  5. BERKELEY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will participate in a fireside chat at the following upcoming investor conference in May:

    • BofA Securities 2022 Healthcare Conference 
      Tuesday, May 10th, at 8:00 am PT

    A webcast of the fireside chat presentation will be accessible via Caribou's website on the Events page. The archived webcast will be available on the Caribou website for 30 days after the event.

    About Caribou's Novel Next-Generation CRISPR Platform
    CRISPR genome editing uses easily designed, modular biological tools to…

    View Full Article
View All Caribou Biosciences Inc. News